Please ensure Javascript is enabled for purposes of website accessibility

OPKO Health Stock Rises Sharply on NFL Coronavirus Testing Deal

By Eric Volkman - Jul 21, 2020 at 8:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The arrangement is the latest in a series of collaborations with professional sports organizations.

Even by the recent standards of frequently high-flying coronavirus stocks, OPKO Health (OPK 7.46%) soared on Tuesday. Investors were cheered by the healthcare company's latest coronavirus testing deal in the professional sports arena.

Jon Cohen, the executive chairman of the company's busy BioReference Laboratories diagnostics subsidiary, disclosed in a TV interview Monday on CNBC's Mad Money that BioReference had agreed in principle with the National Football League to provide coronavirus testing for all 32 of its teams.

A football player leaping for a catch during a night game.

Image source: Getty Images.

In a subsequent regulatory filing, OPKO wrote that "[t]he foregoing agreement in principle with the NFL remains subject to definitive documentation and the parties' execution and delivery thereof." The company has not divulged either the terms or the price of the arrangement.

BioRefence/OPKO seems to be rapidly becoming the go-to coronavirus diagnostics provider in big-ticket athletics.

Last Monday, OPKO announced a similar deal for the National Basketball Association's players, referees, and team and league staff taking part in the league's "season restart" in Orlando, Florida.

That closely followed OPKO's July 9 announcement that it would provide testing for Major League Soccer, again for team members, match officials, and league staffers.

As with the NFL deal, the company hasn't made public the terms or financials of either arrangement.

Of the contract with the higher-profile NBA, OPKO quoted BioReference's Cohen as saying that "[s]imilar to testing for employers trying to get their employees back to work, professional sports entertainment is another integral part of the everyday American experience."

OPKO got a standing ovation from the sidelines for this latest deal. On Tuesday, the stock soared far above the gains of the wider stock market, closing nearly 21% higher.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
$2.45 (7.46%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.